Business Context and Reporting Period
Company: BioRestorative Therapies, Inc. (BRTX)
Filing Type: Form 8-K (Current Report)
Date of Report: February 11, 2026
Event: Commencement and closing of a public equity offering.
Key Financial Metrics and Transaction Details
Offering Structure:
- Common Units: 12,560,715 units sold at $0.35 per unit. Each unit consists of one share of Common Stock and a five-year warrant to purchase one share at $0.35.
- Pre-Funded Units: 1,725,000 units sold at $0.3499 per unit. Each unit consists of a pre-funded warrant (exercise price $0.0001) and a five-year warrant to purchase one share at $0.35.
Proceeds:
- Gross Proceeds: Approximately $5.0 million.
- Net Proceeds: Not explicitly stated; gross proceeds are before deducting placement agent fees and offering expenses.
Placement Agent Fees:
- Cash Fee: 7.0% of aggregate gross proceeds.
- Expense Reimbursement: Up to $100,000 for legal and out-of-pocket expenses.
- Warrant Fee: 350,000 Placement Agent Warrants (7.0% of aggregate shares sold), exercisable at $0.4375 per share (125% of public offering price).
Use of Proceeds: Clinical trials for lead cell therapy candidate BRTX-100, pre-clinical R&D for the metabolic ThermoStem Program, development of the commercial biocosmeceuticals platform, and general corporate purposes/working capital.
Material Changes and Covenants
Market Cap Impact: The offering significantly increases the company's share count and cash position, though specific pre-offering market cap or cash balance is not provided in this filing.
Lock-Up and Issuance Restrictions:
- 90-Day Lock-Up: The Company agreed not to issue, agree to issue, or announce the issuance of Common Stock or convertible securities for 90 days after the closing date (February 13, 2026), subject to exceptions.
- Variable Rate Transaction Ban: The Company agreed not to effect any variable rate transactions for nine months following the closing date.
Guidance, Outlook, and Risks
Management Commentary: Management intends to utilize the capital to advance clinical trials for BRTX-100 and expand the ThermoStem Program and biocosmeceuticals platform.
Risks and Contingencies:
- Dilution: The issuance of Common Units, Pre-Funded Units, and Placement Agent Warrants results in immediate and potential future dilution to existing shareholders.
- Warrant Exercise: All warrants are immediately exercisable, which could impact the share count if exercised.
- Regulatory Status: The offering was conducted pursuant to a registration statement (File No. 333-293322) declared effective by the SEC on February 11, 2026.
Investor Verification Checklist
- Net Proceeds Calculation: Verify the exact net proceeds after deducting the 7% cash fee, up to $100,000 in expenses, and the value of the Placement Agent Warrants.
- Share Count Impact: Confirm the total number of shares outstanding post-offering, including shares from Pre-Funded Warrants and potential warrant exercises.
- Cash Runway: Assess the company's current cash balance (not provided in this 8-K) to determine the extended runway provided by the $5.0 million gross raise.
- Warrant Terms: Review the full text of the warrant agreements (Exhibits 4.1, 4.2, 4.3) for specific exercise conditions, cashless exercise provisions, or anti-dilution adjustments.
- Lock-Up Exceptions: Identify specific exceptions to the 90-day issuance restriction that could allow for further dilution sooner than expected.